Trials / Unknown
UnknownNCT04690062
BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration
Brolucizumab-dbll (BEOVU®) Intravitreal Injection in the Treatment of Dystrophy-related Macular Neovascular Degeneration
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Benha University · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.
Detailed description
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brolucizumab-Dbll | intravitreal injection of Brolucizumab (BEOVU) |
Timeline
- Start date
- 2020-10-25
- Primary completion
- 2022-12-25
- Completion
- 2022-12-30
- First posted
- 2020-12-30
- Last updated
- 2020-12-30
Locations
1 site across 1 country: United Arab Emirates
Source: ClinicalTrials.gov record NCT04690062. Inclusion in this directory is not an endorsement.